RAPT Therapeutics (RAPT) Free Cash Flow (2020 - 2024)
Historic Free Cash Flow for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to -$10.4 million.
- Therapeutics' Free Cash Flow rose 6247.08% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.4 million, marking a year-over-year increase of 1502.55%. This contributed to the annual value of -$83.4 million for FY2024, which is 1502.55% up from last year.
- According to the latest figures from Q4 2024, Therapeutics' Free Cash Flow is -$10.4 million, which was up 6247.08% from -$17.6 million recorded in Q3 2024.
- In the past 5 years, Therapeutics' Free Cash Flow ranged from a high of -$6.4 million in Q2 2020 and a low of -$29.0 million during Q2 2023
- In the last 5 years, Therapeutics' Free Cash Flow had a median value of -$16.5 million in 2022 and averaged -$17.8 million.
- As far as peak fluctuations go, Therapeutics' Free Cash Flow tumbled by 11751.98% in 2021, and later surged by 6247.08% in 2024.
- Therapeutics' Free Cash Flow (Quarter) stood at -$15.5 million in 2020, then tumbled by 35.62% to -$21.1 million in 2021, then dropped by 8.65% to -$22.9 million in 2022, then decreased by 21.5% to -$27.8 million in 2023, then surged by 62.47% to -$10.4 million in 2024.
- Its Free Cash Flow was -$10.4 million in Q4 2024, compared to -$17.6 million in Q3 2024 and -$28.2 million in Q2 2024.